• Skip to main content
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute: Patients and Family
  • UAMS Health
  • Jobs
  • Giving
  • Finding Your Way
    • Prepare for Your First Visit
    • Maps and Directions
    • Accommodations
    • Dining
    • Gift Shop
    • Services & Amenities
  • Treatment
    • Cancer Institute Clinical Resources
    • Clinical Trials
    • Clinics and Centers
    • myChart
    • Appointments
    • Cancer Types
    • Treatment Options
    • Cancer Survivorship Programs
  • Prevention
    • Genetics Program
    • Quit Smoking Programs
    • Lung Cancer Screening
    • Colorectal Cancer Screenings
    • MammoVan
  • Patient Support
    • Support Groups
    • Social Workers
    • Financial Counseling
    • Pharmacist
    • Cancer Nutrition Services
    • Pastoral Care
  1. University of Arkansas for Medical Sciences
  2. Winthrop P. Rockefeller Cancer Institute
  3. Patients and Family
  4. Can a Second Chemotherapy Drug in Addition to Standard Radiation and Temozolomide Extend Your Life or Prevent the Growth and Spread of Your Brain Tumor?

Can a Second Chemotherapy Drug in Addition to Standard Radiation and Temozolomide Extend Your Life or Prevent the Growth and Spread of Your Brain Tumor?

NRG-BN011 is a clinical study for people with a type of brain tumor called a glioblastoma that have not yet received treatment other than surgery for their disease. Participants in this trial will need to be tested to see if their tumor has a biomarker called “methylated” MGMT. A biomarker gives information about how the tumor may respond to treatment. The MGMT methylation test helps predict if the tumor will respond to temozolomide, the standard chemotherapy drug used for glioblastomas. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy.

NRG-BN011 will test to see if the addition of a second chemotherapy drug called lomustine to the usual treatment of radiation and temozolomide chemotherapy can help extend your life or stabilize your cancer. Lomustine is currently approved by the Food and Drug Administration (FDA)- to treat brain tumors, however, it is usually used for recurrent tumors. Researchers are doing this study to find out if this approach is better, the same, or worse than the usual approach for your brain tumor.

Learn More

Posted by Chadley Uekman on December 14, 2022

Filed Under: Clinical Trials

Winthrop P. Rockefeller Cancer Institute LogoWinthrop P. Rockefeller Cancer InstituteWinthrop P. Rockefeller Cancer Institute
Address: 449 Jack Stephens Dr., Little Rock, AR 72205
Parking Deck: 4018 W Capitol Ave., Little Rock, AR 72205
Appointments: (501) 296-1200
Referring Physicians: (501) 686-6080
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy

© 2023 University of Arkansas for Medical Sciences